BCMA
-
US FDA Approves Blenrep for Relapsed/Refractory Multiple Myeloma
GSK’s *Blenrep* (belantamab mafodotin-blmf) has received FDA approval for relapsed or refractory multiple myeloma patients after at least two prior therapies. Backed by the DREAMM-7 trial, *Blenrep* combined with bortezomib and dexamethasone showed a 51% reduction in death risk and tripled progression-free survival compared to a daratumumab-based triplet. *Blenrep* is the only anti-BCMA agent accessible in community settings, with a streamlined REMS program. GSK is actively developing *Blenrep* for earlier lines of treatment, with ongoing trials and data expected in the coming years.
